KA2507

DRUG2 trials

Sponsors

Karus Therapeutics Limited

Conditions

Biliary Tract CancerSolid Tumor, Adult

Phase 1

Safety,Tolerability and MTD KA2507 (HDAC6 Inhibitor) in Patients With Solid Tumours

CompletedNCT03008018

Karus Therapeutics LimitedSolid Tumor, Adult

Start: 2017-08-07End: 2020-06-10Updated: 2020-08-19

Phase 2

A Study of Selective HDAC6 Inhibition With KA2507 in Advanced Biliary Tract Cancer

WithdrawnNCT04186156

Karus Therapeutics LimitedBiliary Tract Cancer

Start: 2020-03-05End: 2023-10-31Updated: 2021-02-03

Related Papers

Preclinical Development and First-in-Human Study of KA2507, a Selective and Potent Inhibitor of Histone Deacetylase 6, for Patients with Refractory Solid Tumors

Clinical Cancer Research2021-05-0460 citations

Abstract CT151: Phase I study of KA2507, a selective HDAC6 inhibitor, in patients with relapsed or refractory solid tumors

Cancer Research2020-08-153 citations

A phase II study of selective HDAC6 inhibition with KA2507 for second-line treatment of advanced biliary tract cancer (ABC-11).

Journal of Clinical Oncology2020-05-203 citations